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Dopamine midbrain neurons within the substantia nigra are particularly prone to degeneration in Parkinson’s disease. Their
selective loss causes the major motor symptoms of Parkinson’s disease, but the causes for the high vulnerability of SN DA
neurons, compared to neighbouring, more resistant ventral tegmental area dopamine neurons, are still unclear. Consequently,
there is still no cure available for Parkinson’s disease. Current therapies compensate the progressive loss of dopamine by
administering its precursor L-DOPA and/or dopamine D2-receptor agonists. D2-autoreceptors and Cav1.3-containing L-type
Ca2+ channels both contribute to Parkinson’s disease pathology. L-type Ca2+ channel blockers protect SN DA neurons from
degeneration in Parkinson’s disease and its mouse models, and they are in clinical trials for neuroprotective Parkinson’s disease
therapy. However, their physiological functions in SN DA neurons remain unclear. D2-autoreceptors tune firing rates and
dopamine release of SN DA neurons in a negative feedback loop through activation of G-protein coupled potassium channels
(GIRK2, or KCNJ6). Mature SN DA neurons display prominent, non-desensitizing somatodendritic D2-autoreceptor responses
that show pronounced desensitization in PARK-gene Parkinson’s disease mouse models. We analysed surviving human SN DA
neurons from patients with Parkinson’s disease and from controls, and detected elevated messenger RNA levels of D2-auto-
receptors and GIRK2 in Parkinson’s disease. By electrophysiological analysis of postnatal juvenile and adult mouse SN DA
neurons in in vitro brain-slices, we observed that D2-autoreceptor desensitization is reduced with postnatal maturation.
Furthermore, a transient high-dopamine state in vivo, caused by one injection of either L-DOPA or cocaine, induced adult-
like, non-desensitizing D2-autoreceptor responses, selectively in juvenile SN DA neurons, but not ventral tegmental area dopa-
mine neurons. With pharmacological and genetic tools, we identified that the expression of this sensitized D2-autoreceptor
phenotype required Cav1.3 L-type Ca
2+ channel activity, internal Ca2+ , and the interaction of the neuronal calcium sensor NCS-
1 with D2-autoreceptors. Thus, we identified a first physiological function of Cav1.3 L-type Ca
2+ channels in SN DA neurons for
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homeostatic modulation of their D2-autoreceptor responses. L-type Ca2+ channel activity however, was not important for
pacemaker activity of mouse SN DA neurons. Furthermore, we detected elevated substantia nigra dopamine messenger RNA
levels of NCS-1 (but not Cav1.2 or Cav1.3) after cocaine in mice, as well as in remaining human SN DA neurons in Parkinson’s
disease. Thus, our findings provide a novel homeostatic functional link in SN DA neurons between Cav1.3- L-type-Ca
2+ chan-
nels and D2-autoreceptor activity, controlled by NCS-1, and indicate that this adaptive signalling network (Cav1.3/NCS-1/D2/
GIRK2) is also active in human SN DA neurons, and contributes to Parkinson’s disease pathology. As it is accessible to
pharmacological modulation, it provides a novel promising target for tuning substantia nigra dopamine neuron activity, and
their vulnerability to degeneration.
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Introduction
Substantia nigra dopaminergic neurons project to the dorsal stri-
atum and are important for voluntary movement. In contrast with
neighbouring dopamine midbrain neurons in the ventral tegmental
area, SN DA neurons are particularly prone to degeneration in
Parkinson’s disease (Bjorklund and Dunnett, 2007; Schultz,
2010). The cause for this selective vulnerability of SN DA neurons
is still unclear, and the typical motor symptoms of Parkinson’s
disease occur when 70% of SN DA neurons are already lost
(Collier et al., 2011; Shulman et al., 2011; Sulzer and Surmeier,
2012). Consequently, there is still no cure for Parkinson’s disease
available, and current Parkinson’s disease therapies try to compen-
sate the progressive loss of striatal dopamine by administering its
precursor L-DOPA (still the gold standard in Parkinson’s disease
therapy) and/or dopamine D2 receptor agonists (Collier et al.,
2011; Gazewood et al., 2013; Olanow and Schapira, 2013).
Understanding the molecular mechanisms of substantia nigra
dopamine function and signalling in health and disease is the pre-
requisite for the development of novel neuroprotective Parkinson’s
disease therapies. Dopamine D2-autoreceptors and Cav1.3 L-
type-Ca2 + channels, calcium load and metabolic stress in SN DA
neurons have already been identified as trigger factors, contribut-
ing to the progressive loss of SN DA neurons, striatal dopamine,
and thus to Parkinson’s disease pathology (Liss and Roeper, 2010;
Surmeier et al., 2012; Ford, 2014), but their interplay is still
unclear.
Dopamine release from striatal axon terminals (and from soma
and dendrites) of SN DA neurons is controlled by their electrical
activity (Beckstead et al., 2007; Rice et al., 2011; Ford, 2014). In
synaptic isolation, SN DA neurons display a so-called ‘pacemaker
activity’ that is intrinsically generated by a concerted interplay of a
range of voltage-gated ion channels, however, with still unclear
individual contributions (Khaliq and Bean, 2010; Liss and Roeper,
2010; Surmeier et al., 2012). Pacemaker activity of SN DA neu-
rons is inhibited by dopamine itself, via therapeutically relevant
dopamine D2-autoreceptors, through activation of inwardly rect-
ifying potassium channels (GIRK2) (Luscher and Slesinger, 2010;
Anzalone et al., 2012; Gantz et al., 2013). Mouse models with
mutations in PARK genes, which lead to familial forms of
Parkinson’s disease (Gasser et al., 2011), show altered substantia
nigra dopamine D2-autoreceptor responses (Goldberg et al., 2005;
Tong et al., 2009), further linking D2-autoreceptor function to
Parkinson’s disease pathology.
The contribution of, in particular, the Cav1.3 L-type-Ca
2 +
channels to pacemaker activity is more controversial than that
of D2-autoreceptors. More precisely, a suggested postnatal
age-dependent switch from a HCN (hyperpolarization-activated
cyclic nucleotide gated) channel driven pacemaker in juvenile
postnatal mouse SN DA neurons to a metabolically more chal-
lenging and Cav1.3 L-type-Ca2 + channel driven pacemaker in
adult SN DA neurons, which would render them more vulner-
able to Parkinson’s disease triggers, is highly disputed (Chan
et al., 2007; Puopolo et al., 2007; Guzman et al., 2009;
Drion et al., 2011; Surmeier et al., 2012). No other calcium
mediated physiological functions of L-type-Ca2 + channels in
SN DA neurons are known. However, blood–brain barrier per-
meable L-type-Ca2 + channel blockers (e.g. isradipine) do pro-
tect highly vulnerable SN DA neurons from degeneration in
Parkinson’s disease and its chronic rodent models (Ritz et al.,
2010; Ilijic et al., 2011; Surmeier et al., 2012), presumably by
reducing substantia nigra dopamine calcium load and metabolic
mitochondrial stress during pacemaking (Guzman et al., 2010;
Surmeier and Schumacker, 2013); and they are already in clin-
ical trials for pharmacological neuroprotective Parkinson’s dis-
ease therapy (Parkinson Study Group, 2013; ClinicalTrials. gov
Identifier: NCT00909545). In contrast to wild-type, SN DA neu-
rons from adult PARK7 (DJ-1) knockout mice display not only
increased L-type-Ca2 + channel-generated metabolic stress
levels, but also rapidly desensitizing somatodendritic D2-auto-
receptor responses (Goldberg et al., 2005; Guzman et al.,
2010), suggesting a possible link between L-type-Ca2 + chan-
nels and D2-autoreceptor function. D2 receptor signalling in
general is complex, depending on additional factors such as
Ca2 + and the neuronal calcium sensor 1 (NCS-1) (Kabbani
et al., 2002), and the signalling mechanisms of somatodendritic
D2-autoreceptors remain poorly understood (Beaulieu and
Gainetdinov, 2011; Ford, 2014).
Here, we detected dramatically higher messenger RNA levels
of D2-autoreceptors and GIRK2 in SN DA neurons from post-
mortem Parkinson’s disease brains compared to those of controls.
To address a possible homeostatic plasticity of D2-autoreceptor
responses, in age-dependent interplay with L-type-Ca2 + chan-
nels, we analysed isolated somatodendritic D2-autoreceptor
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responses as well as related L-type-Ca2 + channel function in SN
DA neurons from juvenile (postnatal Day 13) and adult (postnatal
Day 90) mice in vitro – under control conditions and 3–4 days
after inducing a transient elevation of extracellular dopamine
levels by a single in vivo injection of either L-DOPA or cocaine.
We detected prominent desensitization of D2-autoreceptor re-
sponses in juvenile SN DA neurons that were absent in adult
mice. Non-desensitizing, adult-like D2-autoreceptor responses
could be induced in juvenile substantia nigra (but not ventral
tegmental area) dopaminergic neurons by transient high-dopa-
mine states in vivo. Cav1.3 L-type-Ca
2 + channel function and
Ca2 + -dependent NCS-1/D2-autoreceptor interactions were cru-
cial for this effect. Ncs1 messenger RNA levels were significantly
higher in mouse juvenile SN DA neurons after in vivo cocaine, as
well as in surviving human SN DA neurons in patients with
Parkinson’s disease. Thereby, our findings provide a novel func-
tional link in SN DA neurons between Cav1.3 L-type-Ca
2 + chan-
nels and D2-autoreceptor activity, controlled by NCS-1 levels.
They indicate that this signalling complex (Cav1.3/NCS-1/D2-
autoreceptors) is tuning substantia nigra dopamine activity (and
likely long-term vulnerability), in response to changes in extra-
cellular dopamine levels in mice (cocaine, L-DOPA) as well as in
humans (Parkinson’s disease). Thus, pharmacological modulation
of this signalling network could emerge as a promising novel
approach for modulating substantia nigra dopamine activity, as
well as their vulnerability.
Materials and methods
Animals
Juvenile (postnatal Days 12–14) and adult (approximately postnatal
Day 90) male C57BL/6, Cav1.2 DHP
/ mice and Cav1.3 knockout
mice were bred and genotyped as described previously (Platzer et al.,
2000; Sinnegger-Brauns et al., 2009). NCS-1/ mice were kindly
provided by Prof. Olaf Pongs, Hamburg. Mice were injected: sub-
cutaneously with a mix of 100 mg/kg L-DOPA methyl-ester hydro-
chloride (Sigma) and 200 mg/kg of the peripheral decarboxylase-
inhibitor benserazide hydrochloride (Sigma) or intraperitoneally with
15 mg/kg cocaine hydrochloride (Sigma) in saline (0.9% NaCl,
Braun), or with saline (subcutaneously or intraperitoneally) as control.
In contrast to cocaine, the L-DOPA administration for mice is less
well-established. In divergence to a 4:1 ratio used in humans, we
used L-DOPA and benserazide in 1:2 ratio, as in most studies for
rodents (due to presumably faster metabolism). L-DOPA injections
have been administered subcutaneously as this results in more con-
sistent responses; response failures after intraperitoneal, but not sub-
cutaneous, injections have been described (Lundblad et al., 2004,
2005; Lindgren et al., 2007; Prinz et al., 2013). Because L-DOPA
and cocaine injections both led to the same effects on mouse sub-
stantia nigra dopamine D2-autoreceptor response, we continued our
study with more robust and, for rodents, well-established cocaine
paradigm (Saal et al., 2003). All animal procedures were approved
by the German Regierungspra¨sidium Tu¨bingen (Aktenzeichen: 35/
9185.81-3; TV-No. 921 and 1043) or Darmstadt (V54-19c20/15-
F40/28).
Ultraviolet laser microdissection and
reverse transcription quantitative poly-
merase chain reaction analysis
UV laser microdissection of dopamine neurons from mouse and human
brains using an LMD6000 system (Leica Microsystems), or cytoplasm
harvest were performed essentially as described (Grundemann et al.,
2011). Post-mortem human midbrains were obtained by the German
Brain Bank (BrainNet). All available information on the respective
Parkinson’s disease and control patient’s disease state, comorbidity,
age, and tissue quality is summarized in Supplementary Table 1. We
were not able to obtain information about the therapy of our analysed
patients with Parkinson’s disease. However, it is likely that they were
treated with L-DOPA (and/or D2-agonist).
All experiments on human material were approved by the ethic
commission of Ulm University (247/10-UBB/bal).
Quantification of messenger RNA levels from UV laser microdissected
samples was carried out by real time quantitative PCR after reverse tran-
scription with a GeneAmp 7900HT (Applied Biosystems). For real-time
quantitative PCR assays, TaqMan probes were labelled with FAM as
reporter and a non-fluorescent quencher. Quantitative PCR assay details,
and assay-specific standard curve parameters are given in Supplementary
Table 2. Standard curves for quantitative PCR quantification were gen-
erated using serial dilutions of complementary DNA (3, 0.3 and 0.03 ng),
derived from human substantia nigra tissue RNA (Ambion, Applied
Biosystems), or mouse midbrain messenger RNA (RNeasy MINI kit,
Qiagen), as template in duplicates in at least n = 3 independent quanti-
tative PCR runs. The complementary DNA amount per cell in relation to
the standard was calculated according to:
cDNA amount per cell ¼ S
CtYinterceptð Þ=slope½ 
Nocells  cDNA fraction
Where: S = serial dilution factor of the standard curve (i.e. 10),
Nocells = number of harvested neurons per sample (i.e. 10 for mouse
and 15 for human SN DA neurons), cDNA fraction = fraction of the
UV laser microdissection complementary DNA reaction sample used as
template in the individual quantitative PCR reactions (i.e. 5/17 for
mouse, 1/11 for human substantia nigra dopaminergic neurons). The
unit-magnitude corresponds to the respective standard used, which
defines the unit at the y-intercept (i.e. pg equivalents of standard
complementary DNA, derived from substantia nigra tissue messenger
RNA). As primers for D1 and D5 dopamine receptors were not intron-
spanning, a DNase digestion step (DNA-freeTMkit, Ambion) of UV
laser microdissected samples was included before complementary DNA
synthesis (Liss and Roeper, 2004).
In vitro electrophysiological recordings
from juvenile and adult mouse
brain slices
Mouse brain slice preparations and in vitro electrophysiological patch
clamp recordings from SN DA neurons in 250 mm coronal midbrain
slices of juvenile and adult mice were carried out as described
(Lammel et al., 2008). To block fast synaptic transmission, 10 mM
DNQX (6,7 dinitroquinoxaline-2,3-dione, Tocris) and 10mM gabazine
(SR95531 hydrobromide, Tocris) were added to artificial CSF. To ana-
lyse dopamine auto-inhibition of SN DA neurons in vitro, a minimum
of 5 min stable baseline activity either in gramicidine 100 mg/ml
(Sigma) perforated patch or in cell-attached configuration were re-
corded. This was followed by application of dopamine hydrochloride
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(Sigma) in artificial CSF via bath-perfusion for 15 min and a 20 min
washout. Whole-cell recordings were performed with patch pipettes
containing 0.1 mM EGTA (Sigma) in internal solution (135 mM K-glu-
conate, 5 mM KCl, 10 mM HEPES, 2 mM MgCl2, 0.1 mM NaGTP,
5 mM MgATP, all from Sigma). To test the effects of dopamine an-
tagonists on SN DA neurons, we performed cell-attached recordings of
baseline activity for 10 min, followed by application of 100 mM sulpir-
ide (Tocris) in artificial CSF for another 10 min via bath perfusion. For
L-type-Ca2 + channel and NCS-1 pharmacology, slices were pre-incu-
bated for at least 40 min in artificial CSF containing 300 nM isradipine
(Tocris) or 10 mM D2R/NCS-1 interfering peptide (DNIP)/scrambled
DNIP peptide (Genscript; Saab et al., 2009) before and during cell-
attached recordings. GIRK currents in SN DA neurons were evoked by
local application (10 s) of 100mM dopamine hydrochloride (Sigma) and
recorded in voltage-clamp whole-cell configuration (membrane poten-
tial clamped at 50 mV, analysed with digital filter 500 mHz) in the
presence of 100mM tolbutamide (Sigma) and 20mM ZD 7288 (Tocris)
to block ATP-sensitive potassium channels (K-ATP) and hyperpolariza-
tion-activated cyclic nucleotide-gated channels, respectively. Excitatory
postsynaptic currents were recorded at 70 mV and + 40 mV from SN
DA neurons in whole-cell patch-clamp, and AMPAR/NMDAR ratios
were calculated as described previously (Lammel et al., 2011). Half
maximal effective concentrations (EC50 values) of dopamine for activ-
ity inhibition were calculated from individual cells by applying increas-
ing dopamine concentrations (0.001–100 mM, Sigma), each for 3 min.
Mean frequency at each concentration was normalized to the respect-
ive baseline frequency for each cell. Individual and mean concentra-
tion–response curves were fitted to the Hill equation (curves fitted
with constraints; max = 1, min = 0) to obtain EC50 values. For func-
tional SN DA cell-type identification, cells were re-patched, and SN DA
neuron-specific basal electrophysiological properties (frequency, action
potentials, and sag component) were recorded in whole-cell configur-
ation (Lammel et al., 2008; Ungless and Grace, 2012).
Immunoelectron microscopy
Double-labelling immunoelectron microscopy was performed and rela-
tive abundance of GIRK2 and D2-autoreceptor immunoreactivity in
TH-positive SN DA neurons in control and cocaine injected juvenile
wild-type mice was determined by quantification of immunolabelling
in 60 mm coronal slices, as described by Koyrakh et al. (2005). Primary
monoclonal antibody anti-TH (1–2 mg/ml, Calbiochem) was visualized
by immunoperoxidase reaction and primary guinea pig polyclonal anti-
GIRK2 and rabbit polyclonal anti-D2R antibody (not splice variant spe-
cific, 1–2 mg/ml; Koyrakh et al., 2005; Narushima et al., 2006; Aguado
et al., 2008) by the silver-intensified immunogold reaction. Secondary
antibody mixtures included goat anti-rabbit (Fab fragment; diluted
1:100) coupled to 1.4 nm gold (Nanoprobes), goat anti-guinea pig
(Fab fragment; diluted 1:100) coupled to 1.4 nm gold (Nanoprobes),
and biotinylated goat anti-mouse (diluted 1:100; Vector Laboratories).
Electron photomicrographs for ultrastructural analyses were captured
with a CCD camera (Mega View III; Soft Imaging System) using a
Jeol-1010 electron microscope (Jeol).
Data analysis
Data analysis and graphical representations were performed using
FitMaster software (HEKA Electronics), GraphPad Prism 5 (GraphPad
Software, Inc.), Igor Pro 6 (Wavemetrics Inc.) and Neuroexplorer (Nex
Technologies) for electrophysiological experiments and SDS 2.3
(Applied Biosystems) for quantitative PCR. Statistical analysis was per-
formed in Igor Pro 6, the R project for statistical computing and
GraphPad Prism 5 (GraphPad Software, Inc.). Statistical significance
was set at P5 0.05. Mann-Whitney tests were performed in
GraphPad Prism 5 software and used to determine statistical differ-
ences (*P5 0.05, **P5 0.01 and ***P5 0.001). The coefficient of
variation of the interspike interval was calculated using a Gaussian fit
over the histogram with Neuroexplorer and Igor Pro 6. Coefficient of
variation as [%] = (SD fit) / (mean fit)  100. If not otherwise stated
all data are given as mean  SEM.
Results
Substantia nigra dopaminergic neurons
of patients with Parkinson’s disease
display elevated levels of D2-autore-
ceptors and GIRK2 messenger RNA
compared with controls
Given the important therapeutic role of D2 receptor agonists in
Parkinson’s disease, and of D2-autoreceptors and their main
downstream target GIRK2 for D2-autoreceptor responses that
control substantia nigra dopamine function in health and disease,
we quantified messenger RNA levels of D2-autoreceptors and
GIRK2 in laser-microdissected human SN DA neurons from post-
mortem Parkinson’s disease brains and controls using reverse tran-
scription real-time quantitative PCR (Fig. 1A and B, and
Supplementary Table 1). We detected significantly higher messen-
ger RNA levels for D2-autoreceptors and GIRK2 messenger RNA
in remaining SN DA neurons from Parkinson’s disease brains com-
pared to those of controls (Fig. 1B). D2-autoreceptor/GIRK2 ratios
were not changed (Fig. 1C). These findings point to an altered,
sensitized D2-autoreceptor/GIRK2 signalling control of activity of
SN DA neurons in Parkinson’s disease. To address and define a
possible dopamine-dependent homeostatic plasticity of D2-auto-
receptor/GIRK2 pacemaker control in SN DA neurons, we ana-
lysed isolated somatodendritic dopamine D2-autoreceptor
responses in mouse SN DA neurons. As age-dependent, postnatal
differences in mouse substantia nigra dopamine pacemaker control
have been described (Chan et al., 2007), we analysed juvenile
(postnatal Day 13) as well as adult (postnatal Day 90) mice.
Dopamine D2-autoreceptor-mediated
pacemaker inhibition of SN DA neurons
is pronounced after postnatal
maturation
We compared the unperturbed kinetics and dopamine sensitivities of
D2-autoreceptor-mediated pacemaker inhibition in SN DA neurons
after postnatal maturation in in vitro brain slices of juvenile (postnatal
Day 13) and adult (postnatal Day 90) mice (Fig. 2A and B).
Stimulation of somatodendritic D2-autoreceptors through dopamine
bath application reversibly inhibited spontaneous pacemaker activity
after initial membrane potential hyperpolarization (Fig. 2A). To
ensure full D2-autoreceptor activation, we applied 100 mM dopamine
for 15 min. The kinetics of the dopamine-evoked D2-autoreceptor-
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mediated pacemaker inhibition differed significantly between adult
and juvenile SN DA neurons (Fig. 2A and B). Adult SN DA neurons
did not recover pacemaker activity in the presence of saturating dopa-
mine concentrations. However, SN DA neurons from juvenile mice
displayeda prominent desensitization of the dopamine-induced pace-
maker inhibition, regaining 40% of their baseline firing frequency at
the last minute of dopamine application (Fig. 2E and Supplementary
Table 3). The sensitivity of SN DA neurons to the dopamine-induced
inhibition was 2-fold higher in adult neurons compared to those of
juvenile mice (dopamine EC50 values: juvenile, n = 10:
6.57  1.09 mM; adult, n = 11: 3.29  0.48mM; P = 0.03). The max-
imal dopamine-induced membrane hyperpolarization was not signifi-
cantly different in juvenile and adult SN DA neurons (Supplementary
Table 4). Pacemaker frequency and its precision (expressed as coeffi-
cient of variation of the interspike interval, in %) were similar between
adult and juvenile SN DA neurons under basal conditions in the ab-
sence of dopamine (Fig. 2C and D, and Supplementary Table 5).
Inhibition of D2-autoreceptor function by the D2 anta gonist sulpiride
(100 mM) had no effect on pacemaker frequency or precision of ju-
venile or adult SN DA neurons, arguing against an intrinsic dopamine
tonus, and thus D2-autoreceptor activity in vitro under our recording
conditions (Fig. 2C and D, and Supplementary Table 6).
A single dose of L-DOPA or cocaine
in vivo induces adult-like, stable
D2-autoreceptor responses in
SN DA neurons in vitro
We next studied possible effects of pathophysiologically
and Parkinson’s disease-therapeutically relevant transient high-
dopamine states on mouse substantia nigra dopamine D2-autore-
ceptor responses by injecting them in vivo either with L-DOPA
(the precursor of dopamine, and still the gold standard in
Parkinson’s disease therapy), cocaine (enhancing extracellular
dopamine levels by inhibiting dopamine re-uptake through the
plasmalemma dopamine transporter; Ritz et al., 1987), or saline
(for controls), and analysed D2-autoreceptor responses 4 or 3 days
later, respectively. L-DOPA and cocaine pretreatment strongly af-
fected D2-autoreceptor responses in juvenile SN DA neurons (Fig.
2A, B and E): it converted their desensitizing D2-autoreceptor re-
sponses into non-desensitizing D2-autoreceptor responses that
resembled the adult phenotype (Fig. 2A, B and E, and
Supplementary Table 3). This reduction of desensitization of D2-
autoreceptor responses after in vivo induction of transient high-
dopamine states was a hallmark of juvenile SN DA neurons and
was not observed in juvenile (mesolimbic) ventral tegmental area
dopaminergic neurons (Fig. 2E and Supplementary Table 3).
Neither in vivo L-DOPA nor cocaine treatment significantly altered
the basal spike-frequency or spike-timing precision (coefficient of
variation of the interspike interval) of juvenile or adult substantia
nigra dopamine pacemaker (Fig. 2C and D, and Supplementary
Table 5). As L-DOPA and cocaine injections both induce transient
high-dopamine states by a distinct molecular mechanisms, but had
the same effects on juvenile substantia nigra dopamine D2-auto-
receptor responses, our data strongly suggest that D2-autorecep-
tor responses show a dopamine-dependent plasticity. As the
cocaine injection protocol, in contrast to the L-DOPA protocol, is
well-established for mice (see ‘Materials and methods’ section for
details), we have continued our study with the cocaine paradigm
to induce transient in vivo high-dopamine states (Saal et al.,
2003).
Figure 1 Elevated D2-autoreceptor (AR) and GIRK2 messenger RNA levels in remaining human SN DA neurons from patients with
Parkinson’s disease (PD). (A) Neuromelanin-positive human SN DA neurons (SN DA) (before and after UV laser microdissection) from post
mortem Parkinson’s disease and control midbrain sections (for details, see Supplementary Table 1). (B) Real-time quanititative PCR results
identified significantly higher relative messenger RNA levels for D2-autoreceptors and GIRK2 in human SN DA neurons from Parkinson’s
disease brains compared to controls (ctr) (D2-autoreceptors: controls, n = 26, 1  0.19; Parkinson’s disease, n = 39, 4.25  0.73;
****P50.0001; Mann-Whitney test; GIRK2: controls, n = 25, 1  0.25; Parkinson’s disease, n = 34, 6.31  1.12; ****P50.0001;
Mann-Whitney test). (C) D2/GIRK2 ratios were not different in SN DA neurons from controls and Parkinson’s disease patients. All data are
shown as the mean  SEM.
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Figure 2 In vivo transient high-dopamine states (induced by L-DOPA or cocaine) cause adult-like non-desensitizing dopamine D2-
autoreceptor responses in juvenile SN DA neurons (SN DA). (A) Representative SN DA neuron pacemaker activity recordings from in vitro
brain slices of adult and juvenile wild-type mice, pretreated (4 or 3 days, respectively) in vivo with saline, L-DOPA, or cocaine (perforated/
cell-attached patch-clamp). Dopamine bath application is indicated by red bars. (B) Normalized frequencies plotted against time for all
analysed SN DA neurons revealed pronounced desensitization of D2-autoreceptor responses in juveniles (n = 14) compared to adults
(n = 10), as well as adult-like, non-desensitizing D2-autoreceptor responses in juvenile SN DA neurons after in vivo L-DOPA (n = 15) or
in vivo cocaine (coc; n = 12), compared to controls (ctr; saline, n = 14). (C) Bar graphs show no change in mean frequencies before and
after sulpiride application in SN DA neurons from controls, as well as after saline, L-DOPA, or cocaine in vivo injections, before dopamine
application. (D) Pacemaker precision [given as coefficient of variation of interspike interval values, (CV ISI)] of juvenile and adult SN DA
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(continued)
Functional expression of D2-auto-
receptors and GIRK2 is not altered in
juvenile SN DA neurons after in vivo
induction of a transient high-dopamine
state
We next addressed the underlying molecular mechanism of
altered, adult-like D2 autoreceptor responses in juvenile SN DA
neurons after in vivo induction of a transient high-dopamine
state by cocaine. We confirmed that mouse SN DA neurons pre-
dominantly express GIRK2 messenger RNA alone, together with
D2 dopamine receptor messenger RNA (Fig. 3A, D2 receptor and
GIRK2 were co-expressed in 100% of analysed SN DA neurons,
n = 85, without other GIRKs in 80%). Other dopamine receptor
subunits were not detected or only in a small fraction of SN DA
neurons (Fig. 3A; D1: n = 1, D5: n = 2, D3: n = 3, D4: n = 0 out of
39 TH- and D2-positive SN DA neurons). Although most SN DA
neurons co-expressed both the short D2s and the long D2l recep-
tor-splice variants (65%, Fig. 3A), 35% expressed only one
splice variant (only D2l: n = 23 of 85; only D2s: n = 6 of 85). As
all analysed SN DA neurons showed typical functional D2-auto-
receptors responses, we conclude that both D2s and D2l alone can
act as functional D2-autoreceptors in mouse SN DA neurons. To
probe whether the relative expression of the D2-autoreceptor
splice variants in SN DA neurons was altered after cocaine injec-
tion, we quantified D2 short and long variants, and calculated
D2l/s ratios in SN DA neurons from juvenile mice with and with-
out cocaine treatment. We found no change in D2s or D2l mes-
senger RNA levels or D2l/s ratios in juvenile SN DA neurons after
cocaine (Fig. 3A). We also quantified D3 and D4 messenger RNA
in SN DA neurons from juvenile mice without and after cocaine.
However, we detected no expression of D3 or D4 using real-time
quantitative PCR, neither in controls or after cocaine (n = 6 probes
each, data not shown). These data rule out that altered expression
of D2 splice variants or other D2-type receptors (D3, D4) are
causing the observed functional change in substantia nigra dopa-
mine D2-autoreceptor desensitization after in vivo cocaine. The
reduced desensitization of D2-autoreceptors in juvenile SN DA
neurons after in vivo induced transient high-dopamine states
was also not associated with an enhanced expression of either
D2-autoreceptors or GIRK2 (Fig. 3). D2-autoreceptor messenger
RNA and immunoreactivity (Fig. 3A and B) was unaffected after
cocaine. GIRK2 messenger RNA (Fig. 3A) and its functional chan-
nel activity (Fig. 3C) were downregulated rather than upregulated.
We also detected no change in the dopamine transporter and
vesicular monoamine transporter (Vmat2, also known as
Slc18a2) messenger RNA ratio in juvenile SN DA neurons after
cocaine, the transporters that define dopamine uptake and release
capacity, respectively (Fig. 3D).
Cav1.3 L-type calcium channel function
and internal Ca2+ is crucial for
non-desensitizing D2-autoreceptor
responses induced by high-dopamine
states in vivo, in juvenile SN DA
neurons
As calcium signalling is not only critical for the control of D2-
receptor desensitization in general, but also triggers selective sub-
stantia nigra dopamine degeneration in Parkinson’s disease, and as
L-type-Ca2 + channel-blockers protect for Parkinson’s disease in
humans and mice, we evaluated a potential role of internal cal-
cium ([Ca2 + ]i) and L-type-Ca
2 + channels for the expression of the
high dopamine-dependent, non-desensitizing D2-autoreceptors in
juvenile SN DA neurons. We first tested if the cocaine effect on
D2-autoreceptors depended on unperturbed [Ca2 + ]i by buffering
[Ca]i with 0.1 mM EGTA using whole cell dialysis (Fig. 4A and
Supplementary Table 3). EGTA buffering did not affect the kinetics
of dopamine autoinhibition in juvenile substantia nigra dopamine
neurons in saline treated animals compared to those recorded in
perforated patch. However, after cocaine treatment, D2-autore-
ceptor responses still displayed prominent desensitization, in con-
trast with the non-desensitizing responses after cocaine recorded
in perforated patch (Fig. 4A). These data indicate a complex de-
pendence of cocaine-induced D2-autoreceptor potentiation on
intracellular Ca2 + . They also emphasize the importance of analys-
ing D2-autoreceptors signalling in non-perturbed recording config-
urations, as the cocaine effect is absent in whole cell recordings.
We next tested if L-type-Ca2 + channels could provide the Ca2 +
source for Ca2 +-dependent control of D2-autoreceptor responses,
by continuous treatment of slices with the selective L-type Ca2 +
channel blocker isradipine (300 nM), which is already in clinical
trials as neuroprotective therapy for Parkinson’s disease
(Striessnig et al., 2006; Simuni et al., 2010; Surmeier et al.,
2012), before, during and after dopamine application. Isradipine
completely abolished the effect of in vivo cocaine treatment on
D2-autoreceptor desensitization in juvenile SN DA neurons (Fig.
4B and F, and Supplementary Table 3), revealing a crucial role of
these channels for the expression of the here described cocaine
effect.
Another important observation was that although 300 nM isra-
dipine modified the cocaine response, it did not significantly
reduce basal pacemaker frequency or its precision in juvenile or
adult SN DA neurons (Fig. 4D and E, and Supplementary Table 5).
Figure 2 Continued
neurons was also not altered after sulpiride application, as well as after saline, L-DOPA, or cocaine in vivo injections. (E) D2-autoreceptor
responses of mouse substantia nigra and ventral tegmental area dopaminergic neurons represented as mean activity of respective
dopaminergic neurons at the last minute of dopamine application (15 min). Data are shown as the mean  SEM. Data values detailed in
Supplementary Tables 3, 5 and 6.
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Figure 3 Functional expression of D2-autoreceptors (AR) [D2 short/long variants (s/l), D3, D4] and GIRK2 is not altered in juvenile SN
DA neurons after in vivo induction of a transient high-dopamine state. (A, top) Agarose gel electrophoresis of multiplex nested reverse
transcritpion PCR products identified D2 receptor (both splice variants) and GIRK2 as the molecular components of the D2-autoreceptors
in SN DA neurons. Note the absence of D3 and D4 receptor, as well as GIRK1. Bottom: Quantitative analysis (reverse transcritpion
quantitative PCR) of laser-microdissected (LMD) juvenile SN DA neurons showed no change in the ratio of D2 long and D2 short splice
variant expression levels, after cocaine in single SN DA neurons (saline, n = 15, 1  0.12; cocaine, n = 15, 0.85  0.07; P = 0.29; Mann-
Whitney test). Further, no changes in D2-autoreceptors (relative messenger RNA levels normalized to saline controls: saline, n = 18,
1  0.14; cocaine, n = 19, 0.90  0.08; P = 0.73; Mann-Whitney test), D3 or D4 receptor messenger RNA (data not shown, as no signal
was detected. D3 receptor: saline, n = 6; cocaine: n = 6; D4 receptor: saline, n = 6; cocaine, n = 6) were detected. GIRK2 messenger RNA
levels were also decreased rather than increased after in vivo cocaine (saline, n = 19, 1  0.15; cocaine, n = 20, 0.62  0.07; *P = 0.04;
Mann-Whitney test; note the significantly altered D2-autoreceptor/GIRK2 ratios after cocaine due to decreased GIRK2-levels; saline,
n = 18, 1  0.08; cocaine, n = 19, 1.57  0.12; **P = 0.002; Mann-Whitney test). All data given as mean  SEM normalized to controls.
(B, left) Pre-embedding double-immunolabelling at electron microscopy level for D2-autoreceptors and GIRK2 in TH-positive SN DA
neurons 3 days after saline/cocaine in vivo injection of juvenile wild-type mice (n = 3 animals each; arrows point to immunogold labelling
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In SN DA neurons, the pore-forming 1-subunits of both brain
L-type-Ca2 + channels, Cav1.2 and Cav1.3, are expressed (Olson
et al., 2005; Sinnegger-Brauns et al., 2009). Since isradipine in-
hibits both isoforms, we cannot distinguish which of these chan-
nels mediate its pharmacological effect on SN DA neurons. To
address this question, we took advantage of homozygous
Cav1.2 DHP
/ mutant mice. These mice express Cav1.2 L-
type-Ca2 + channels with normal function, but their high sensitivity
to isradipine is eliminated by a single mutation within the DHP-
binding pocket (Sinnegger-Brauns et al., 2004; Striessnig and
Koschak, 2008). Thus, Cav1.2-mediated isradipine effects are
absent in these mice, whereas drug effects through Cav1.3 are
unaffected. In SN DA neurons from Cav1.2 DHP
/ mutant
mice the effect of isradipine was indistinguishable from wild-type
(Fig. 4C and F, and Supplementary Table 3). As the isradipine
concentration used was very low (300 nM), and no other targets
are known to be affected at this concentration, Cav1.3 remains
the only plausible molecular transducer for the cocaine-induced,
calcium-dependent, and isradipine-sensitive change in substantia
nigra dopamine D2-autoreceptor responses.
We also assessed the role of Cav1.3 more directly in Cav1.3-
deficient mice (Cav1.3 knockout mice) (Platzer et al., 2000). In this
model, although basal substantia nigra dopamine pacemaker ac-
tivity remained unaffected, the constitutive absence of Cav1.3 ac-
tivity throughout development prevented the postnatal wild-type
substantia nigra dopamine D2-autoreceptor phenotypes, as the
non-desensitizing ‘adult’ D2-autoreceptor responses were present
in SN DA neurons from both juvenile as well as adult Cav1.3
knockout mice (Supplementary Fig. 1 and Supplementary Table
7). Because of absence of the juvenile desensitizing D2-autorecep-
tor phenotype, we did not further study in vivo cocaine effects in
Cav1.3 knockout mice.
Taken together the findings from both mouse models reveal a
novel functional role of Cav1.3 L-type-Ca
2 + channels for both the
development of age-dependent D2-autoreceptor differences in SN
DA neurons, and for the switch of juvenile desensitizing D2-auto-
receptor response to those of adult substantia nigra dopamine
neurons in response to a transient in vivo high-dopamine state.
At the messenger RNA level, we found no change in expression
of Cav1.2 and Cav1.3 L-type-Ca
2 + channel pore-forming 1-sub-
units in mouse SN DA neurons after in vivo cocaine (Fig. 4G).
Also, we found no change in expression levels of Cav1.2 and
Cav1.3 in remaining human SN DA neurons of patients with
Parkinson’s disease compared to controls (Fig. 4G).
As Cav1.2 and Cav1.3 expression were not altered, we probed
for altered AMPA/NMDAR ratios in juvenile cocaine-treated SN
DA neurons after in vivo cocaine as an alternative calcium source,
causing synaptic plasticity after cocaine in adult ventral tegmental
area dopamine neurons (Ungless et al., 2001; Lammel et al.,
2011). However, we detected no change in AMPAR/NMDAR-
mediated excitatory postsynaptic currents after in vivo cocaine
in juvenile SN DA neurons (Supplementary Fig. 2).
Cocaine induced, adult-like, D2-auto-
receptor responses in juvenile substan-
tia nigra dopaminergic neurons are
mediated by NCS-1
We next explored a possible contribution of NCS-1 for Cav1.3
dependent control of D2-autoreceptor responses in juvenile SN
DA neurons, in response to in vivo transient high-dopamine,
induced by cocaine. NCS-1 can directly interact with postsynaptic
D2 receptors in a Ca2 +-dependent manner and inhibit receptor
desensitization by preventing its phosphorylation through G pro-
tein-coupled receptor kinase 2 (GRK2, also known as ADRBK1),
and thus beta-arrestin-mediated receptor internalization (Kabbani
et al., 2002). We analysed mouse substantia nigra dopamine D2-
autoreceptor responses in the presence of a membrane-permeable
peptide, DNIP (D2R/NCS-1 interfering peptide), which physically
blocks NCS-1 binding to D2 receptor (Saab et al., 2009). As con-
trol, a membrane-permeable, scrambled version of the peptide
(scrambled DNIP) was used, which did not influence basal pace-
maker activity or the kinetics of the D2-autoreceptor response of
SN DA neurons after in vivo cocaine (Figs 5A, 5B and
Supplementary Tables 3 and 5). Similar to 300 nM of the substan-
tia nigra dopamine- and Parkinson’s disease-protective L-type-
Ca2 + channel-blocker isradipine, 10 mM DNIP completely abol-
ished the cocaine effect on D2-autoreceptor responses in juvenile
SN DA neurons. With NCS-1/D2-autoreceptor interaction blocked,
D2-autoreceptors displayed rapid desensitization, similar to that
seen without cocaine pretreatment (Fig. 5A and B, and
Supplementary Table 3). To prove that NCS-1 function is neces-
sary and sufficient for modulating D2-autoreceptor desensitization
in SN DA neurons, we analysed D2-autoreceptor responses in a
Figure 3 Continued
at extrasynaptic plasma membrane and crossed arrows at intracellular sites). Right: No significant differences in immunoreactivity or
subcellular localization of D2-autoreceptor protein (n = 3 animals each; saline, 1107.3  8.7; cocaine, 1034.3  33.5; P = 0.2; Mann-
Whitney test), and GIRK2 protein (n = 3 animals each; saline, 1408.3  9.1; cocaine, 1396.3  7.1; P = 0.4; Mann-Whitney test). (C, left)
Representative traces of dopamine evoked GIRK currents in juvenile SN DA neurons recorded in whole-cell voltage-clamp in vitro in the
presence of 100mM tolbutamide and 20 mM ZD7288 to block ATP-sensitive potassium channels (K-ATP) and hyperpolarization-activated
cyclic nucleotide-gated (HCN) channels. Right: Mean dopamine-evoked GIRK current amplitudes were not increased, but significantly
reduced after in vivo cocaine in juvenile SN DA neurons (saline, n = 12, 101.48  7.69 pA; cocaine, n = 10, 75.88  12.74 pA; *P = 0.03;
Mann-Whitney test). (D) DAT/VMAT2 messenger RNA ratios in juvenile SN DA neurons, defining their individual dopamine-release
capacity, were not altered after in vivo cocaine (normalized ratios: saline, n = 8, 1  0.14; cocaine, n = 8, 1.23  0.13; P = 0.29;
Mann–Whitney test). Data are given as mean  SEM.
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Figure 4 Ca2 +and Cav1.3 L-type-Ca
2 + channels are crucial for adult-like, non-desensitizing D2-autoreceptor responses, induced by a
transient high-dopamine state in vivo, in juvenile SN DA neurons. (A) Mean activity of substantia nigra dopaminergic neurons at the last
minute of dopamine application [15 min, recorded in perforated patch (pp) juvenile: saline, n = 14; cocaine, n = 12] compared to those
recorded in whole cell (wc) configuration with 0.1 mM EGTA (whole cell: juvenile: saline, n = 6; cocaine, n = 7) to buffer free [Ca2 + ]i in
juvenile SN DA neurons. Note the absence of cocaine-induced stabilization of D2-autoreceptor responses in whole cell compared to
unperturbed perforated patch recordings. (B) Experiments as in Fig. 1 but in the presence of the L-type-Ca2 + channel blocker isradipine
(300 nM, represented with blue bar). Isradipine completely blocked changes in kinetics of D2-autoreceptor desensitization of SN DA
neurons, after transient high-dopamine state induced by cocaine, in wild-type mice (saline, n = 7; cocaine, n = 7). (C) Similar experiments
as in B, but using Cav1.2 DHP
/ mice (with Cav1.2 L-type-Ca
2 + channels, insensitive to isradipine; saline, n = 6; cocaine, n = 9).
Application of 300 nM isradipine still abolished cocaine D2-autoreceptor response potentiation, pointing to the crucial role of Cav1.3
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general NCS-1/ mouse, lacking NCS-1 in all cells. Substantia
nigra dopaminergic neurons of NCS-1/ mice displayed rapidly
desensitizing D2-autoreceptors responses already under control
conditions that were not converted to a sensitized response after
in vivo cocaine, confirming that NCS-1 is necessary and sufficient
for preventing D2-autoreceptor desensitization in mouse SN DA
neurons (Fig. 5A and B ,and Supplementary Tables 3 and 5).
To address why Ca2 + -dependent NCS-1/D2-autoreceptors
interactions seem to be more prominent after cocaine (and thus
D2-autoreceptors desensitization was reduced), we quantified
NCS-1 messenger RNA. We found that NCS-1 messenger RNA
levels were 2-fold higher in juvenile SN DA neurons after
in vivo cocaine (P = 0.0001; Fig. 5C). This could explain enhanced
L-type-Ca2 + channel-dependent Ca2 + -stimulated NCS-1/D2-
autoreceptor signalling, without increased expression of L-type-
Ca2 + channels, but due to increased NCS-1 availability. This
would allow SN DA neurons to adapt the degree of their dopa-
mine D2-autoreceptor activity to homeostatic dopamine chal-
lenges, by tuning NCS-1 expression. To address if a similar
increased NCS-1 expression is also present in human SN DA neu-
rons in Parkinson’s disease, hinting to a corresponding homeostatic
adaptive change in D2-autoreceptors signalling, we quantified
messenger RNA levels of NCS-1 in human SN DA neurons from
controls and endstage Parkinson’s disease brains (Fig. 5C, right).
Indeed, similar to mice after cocaine, we detected 2-fold higher
messenger RNA levels of NCS-1 in remaining SN DA neurons from
Parkinson’s disease brains (Fig. 5C). Thus, increased NCS-1/D2-
autoreceptor signalling, downstream of Cav1.3, may also fine-tune
human substantia nigra dopamine neuron activity in Parkinson’s
disease. It might (compensatory) allow remaining dopamine to
reduce firing, activity-associated rhythmic cellular calcium load,
and thus vulnerability of SN DA neurons.
Discussion
In summary, our data indicate a flexible D2-autoreceptor signalling
in SN DA neurons, controlling their pacemaker activity, during
maturation, and in response to pathophysiological in vivo dopa-
mine challenges in mice, which could also be translated to human
Parkinson’s disease pathology. Our findings describe the neuronal
calcium sensor NCS-1 as a novel link between two major molecu-
lar players, modulating the activity of SN DA neurons as well as
their vulnerability to degeneration in Parkinson’s disease: Cav1.3
L-type-Ca2 + channels and D2-autoreceptors (Beaulieu and
Gainetdinov, 2011; Surmeier et al., 2012; Ford, 2014). We
show that the degree of somatodendritic D2-autoreceptor desen-
sitization in juvenile mouse SN DA neurons, in response to in vivo
transient high-dopamine states, depends on Cav1.3 channels, as
well as on the calcium dependent NCS-1 interaction with D2-
autoreceptors. Our findings link flexible D2-autoreceptor desensi-
tization with Cav1.3 L-type-Ca
2 + channel function, through func-
tional expression of NCS-1, and point to a role of this signalling
network for adaptive changes in substantia nigra dopamine
neuron activity due to altered extracellular dopamine levels. Our
data also provide a fresh look at the molecular mechanisms
involved in substantia nigra dopamine neuron activity control, as
well as their pathophysiology in Parkinson’s disease and its dopa-
mine-mimetic therapy.
Dopamine D2 receptors are important for proper function of
dopamine midbrain neurons, and are important pharmacological
targets for therapy of schizophrenia (antagonist; Ginovart and
Kapur, 2012), and in particular Parkinson’s disease (agonist;
Yamamoto and Schapira, 2008). Somatodendritic D2-autorecep-
tors are coupled to GIRK2 potassium channels, and reduce activity
and excitability of SN DA neurons in response to locally released
dopamine in the midbrain (Beckstead and Williams, 2007; Gantz
et al., 2013; Ford, 2014). Dysfunction of these somatodendritic
D2-autoreceptors is linked to Parkinson’s disease pathology (Ford,
2014); however their exact functions in health and disease are by
far not as well examined as the function of pre- and particularly
postsynaptic D2 receptors (Beckstead et al., 2007; Ford et al.,
2010; Bello et al., 2011; Anzalone et al., 2012; Ford, 2014).
To date, only the short D2-autoreceptor splice variant, D2s has
been identified as the D2-autoreceptor (Usiello et al., 2000;
Beaulieu and Gainetdinov, 2011; Ford, 2014). Our combined
functional and molecular single cell analysis strongly suggests
that the long D2l splice variant alone can build functional D2-
autoreceptors in SN DA neurons. Recent reports confirm this
claim as expression of either D2s or D2l alone in SN DA neurons
of D2 receptor knockout mice restored D2 agonist-induced acti-
vation of GIRKs (Neve et al., 2013). In accordance with the lit-
erature, reviewed in Ford (2014), we also show that the other D2-
type receptors (D3, D4) are not important for D2-autoreceptor
function, or its homeostatic plasticity in mouse SN DA neurons.
We did not quantify excitatory acting D1-type dopamine receptors
(D1 and D5), as their messenger RNAs were almost never de-
tected in SN DA neurons (Fig. 3A), they are not coupled to
Figure 4 Continued
L-type-Ca2 + channels in this process. (D and E) Isradipine (300 nM) did not reduce basal pacemaker frequencies or activity pattern
(coefficient of variation of interspike interval) of juvenile SN DA neurons. (F) Activity of SN DA neurons at the last minute of dopamine
application. Data values detailed in Supplementary Tables 3 and 5. (G) Quantitative analysis (reverse transcription quantitative PCR) of
laser-microdissected (LMD) mouse and human SN DA neurons detected no change in messenger RNA levels of Cav1.2 or Cav1.3, the
pore-forming alpha subunit of L-type-Ca2 + channels in the brain, after in vivo cocaine (mice, left) or in Parkinson’s disease compared to
controls (humans, right). Normalized expression levels: mouse: Cav1.2: saline, n = 18, 1  0.01; cocaine, n = 18, 1.01  0.02; P = 0.92;
Cav1.3: saline, n = 17, 1  0.17; cocaine, n = 18, 0.81  0.16; P = 0.37; Mann-Whitney test. Human: Cav1.2: control, n = 4, 1  0.01;
Parkinson’s disease, n = 5, 0.90  0.11; P = 0.43; Cav1.3: control, n = 16, 1  0.16; Parkinson’s disease, n = 33, 1.14  0.14; P = 0.64;
Mann-Whitney test). Data are shown as mean  SEM.
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inhibitory GIRK2 receptors, and have only been functionally
described postsynaptically (Vallone et al., 2000; Beaulieu and
Gainetdinov, 2011).
We have previously shown that D2-autoreceptor responses are
not homogeneous within distinct types of substantia nigra and
vental tegmental area dopaminergic neurons from adult mice
(Lammel et al., 2008). Now we show significantly elevated mes-
senger RNA levels of D2-autoreceptors, as well as GIRK2 in re-
maining human SN DA neurons in Parkinson’s disease, pointing to
altered D2-autoreceptor function in the course of the disease. We
Figure 5 Adult-like, non-desensitizing D2-autoreceptor responses in SN DA neurons are mediated by the neuronal calcium sensor 1
(NCS-1). (A, left) Normalized frequency plots show that non-desensitizing D2-autoreceptor responses of juvenile SN DA neurons after
in vivo cocaine were completely blocked by 10 mM DNIP (cell-permeant D2R/NCS-1 interfering peptide, n = 8), whereas the scrambled
version had no effect (10 mM srDNIP, n = 6). (Right) Respective analysis (as in A) of a general NCS-1 knockout mouse (NCS-1/)
demonstrated that NCS-1 is crucial for non-desensitizing D2-autoreceptor responses of juvenile SN DA neurons. (B) Activity of SN DA
neurons from (A) at the last minute (15 min) of dopamine application (note the significantly pronounced D2-autoreceptor desensitization
in NCS-1/ already under control conditions). Data values detailed in Supplementary Table 3. (C) Reverse transcrition quantitative PCR
analysis of mouse and human SN DA neurons identified 2-fold higher Ncs-1 messenger RNA levels after cocaine (saline, n = 36, 1  0.08;
cocaine, n = 32, 1.94  0.15; ***P = 0.0001; Mann-Whitney test), as well as in Parkinson’s disease, compared with controls (control,
n = 27, 1  0.20; Parkinson’s disease, n = 33, 2.60  0.27; ****P50.0001; Mann-Whitney test). (D) Cartoon depicting molecular
components of a novel Cav1.3/NCS-1/D2-autoreceptor/GIRK2 signalling network in SN DA neurons, which allows homeostatic adap-
tation of their inhibitory dopamine D2 responses, and thus their pacemaker activity.
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addressed a general possibility of a non-static, but plastic, D2-
autoreceptor response in SN DA neurons in mice, and found
that somatodendritic D2-autoreceptor responses of SN DA neu-
rons are not uniform during postnatal maturation, but display
prominent desensitization in juvenile mice (postnatal Day 13),
which is absent in adults (postnatal Day 90). Furthermore we
show that adult-like, non-desensitizing D2-autoreceptor responses
could be induced in juvenile SN DA neurons by a transient high-
dopamine state in vivo (via L-DOPA or cocaine). Most import-
antly, we identified that Cav1.3 L-type-Ca
2 + channels are crucial
for controlling dopamine-dependent D2-autoreceptor desensitiza-
tion in mouse SN DA neurons, as they provide the calcium source
for a Ca2 + dependent NCS-1/D2-autoreceptor interaction, which
prevents D2-receptor desensitization (Beaulieu and Gainetdinov,
2011). That defines, to our knowledge, a first physiological func-
tion of L-type-Ca2 + channels in SN DA neurons. Our Cav1.3
knockout and Cav1.2 DHP
/ analysis ruled out Cav1.2 and iden-
tified Cav1.3 as the crucial L-type-Ca
2 + channel for this function.
The here identified role of Cav1.3 L-type-Ca2 + channels, for
NCS-1 mediated modulation of D2-autoreceptors and activity of
SN DA neurons, has not yet been described. Postsynaptically, in
striatal medium spiny neurons, D2 receptors upstream of L-type-
Ca2 + channels can reduce L-type-Ca2 + channel activity through a
calcineurin signalling cascade (Hernandez-Lopez et al., 2000;
Olson et al., 2005). Also postsynaptically, in hippocampal neurons,
reduced desensitization of D2-receptors, due to NCS-1/D2-auto-
receptor interaction and thereby prevention of phosphorylation
through GRK2, and thus receptor internalization, has been re-
ported (Jo et al., 2008; Saab et al., 2009). Accordingly, we hy-
pothesize that after induction of transient elevated dopamine
levels, by in vivo L-DOPA or cocaine, D2-autoreceptor responses
desensitize less in juvenile SN DA neurons due to increased NCS-1
expression and its higher availability for binding to D2-autorecep-
tors, leading to reduced GRK2 phosphorylation and D2-autorecep-
tor internalization in response to prolonged dopamine exposure.
The in vitro Ca2 + buffering experiments (EGTA) as well as the
DNIP experiments and the analysis of the Ncs1/ mice further
support this hypothesis. We hypothesize accordingly that in re-
maining SN DA neurons in Parkinson’s disease, due to increased
expression of NCS-1, D2 and GIRK2, inhibitory D2-autoreceptor
responses are also sensitized.
At the messenger RNA level, Cav1.3 (or Cav1.2) expression was
not increased, neither in mouse SN DA neurons after cocaine nor
in human SN DA neurons in Parkinson’s disease. However, our
data do not exclude altered Cav1.3 activity. Evidence for enhanced
Cav1.3 protein expression in SN DA neurons in Parkinson’s disease
compared to controls has been described in immunohistochemical
experiments (Hurley et al., 2013). However, although L-type-
Ca2 + channel activity is necessary, increased calcium entry
through L-type-Ca2 + channels is not necessarily required to ac-
count for the functional D2-autoreceptor plasticity observed in
mice, as the detected higher NCS-1 levels would provide
enhanced calcium-dependent NCS-1/D2 signalling, preventing de-
sensitization. Indeed, NCS-1 expression is stimulated by calcineurin
(Hamasaki-Katagiri and Ames, 2010), a phosphatase that itself is
stimulated by D2 receptor activity (Greengard et al., 1999). Thus,
a transient increase in dopamine, that leads to increased
D2-autoreceptors stimulation, would be sufficient to increase cal-
cium-dependent NCS-1 expression, e.g. via calcineurin-stimula-
tion, and thus to increased calcium-dependent NCS-1/D2
interaction, in a negative feedback loop.
Our finding that pharmacological L-type-Ca2 + channel-block
did not significantly reduce basal pacemaker frequency or its pre-
cision in juvenile or adult mouse SN DA neurons clearly argues—at
least under our recording conditions—against a crucial role of L-
type-Ca2 + channels in SN DA neurons for pacemaker activity. This
disputes a previously reported switch from HCN channel to a
metabolically more challenging L-type-Ca2 + channel-driven pace-
maker in SN DA neurons, that would render them particularly
vulnerable to degeneration during postnatal maturation (Bean,
2007; Chan et al., 2007; Puopolo et al., 2007; Drion et al.,
2011; Surmeier et al., 2012)
We also detected no cocaine-induced changes in AMPA/NMDA
ratios in juvenile SN DA neurons, as described for adult ventral
tegmental area dopamine neurons (Ungless et al., 2001; Lammel
et al., 2011). In contrast, we observed a cocaine-induced, Cav1.3,
calcium and NCS-1-dependent substantia nigra-specific ‘enhance-
ment’ of D2-autoreceptor function in vitro, which could act as an
excitability brake and thus counteract or prevent excitotoxicity and
degeneration of substantia nigra dopamine neurons (Dong et al.,
2009). The finding that SN DA neurons from PARK mice (with
particularly high vulnerable SN DA neurons) display D2-autorecep-
tor responses with significantly enhanced desensitization (Goldberg
et al., 2005; Tong et al., 2009) would support this interpretation.
Although L-type-Ca2 + channels seem not to be crucial for sub-
stantia nigra dopamine pacemaking, there is accumulating evi-
dence that the pacemaker activity of SN DA neurons drives
somatodendritic Ca2 + entry through L-type-Ca2 + channels, thus
generating a neurotoxic Ca2 + load that triggers their degeneration
(Chan et al., 2007; Puopolo et al., 2007; Khaliq and Bean, 2010;
Surmeier and Schumacker, 2013). Reduction of substantia nigra
dopamine activity through a sensitized D2-autoreceptor response
could therefore counteract this neurotoxic Ca2 + load. This would
especially occur in response to transient high dopamine states,
induced e.g. by dopamine-mimetic therapy. Thus, Cav1.3/Ca
2 +
dependent NCS-1 modulation of D2-autoreceptor desensitization
may emerge as a homeostatic response in human SN DA neurons
in Parkinson’s disease, reducing electrical activity and protecting
surviving SN DA neurons from acute overexcitability (to compen-
sate the progressive dopamine loss) and excitotoxicity (Dong
et al., 2009; Liss and Roeper, 2010; Callaghan et al., 2012).
In this view, our data also raise an important issue regarding the
Parkinson’s disease protective effects of L-type-Ca2 + channel
blockers in humans (Ritz et al., 2010; Marras et al., 2012;
Pasternak et al., 2012). We have no information about the ther-
apy of our patients with Parkinson’s disease; however, it is likely
that they were treated with L-DOPA (and/or D2 agonist). If in
Parkinson’s disease, pathophysiology and/or dopamine-mimetic
treatment induces—potentially protective—sensitized D2-autore-
ceptor responses in aged SN DA neurons, then this may be in-
hibited by treatment with L-type-Ca2 + channel blockers.
The resulting enhancement of substantia nigra activity would
counteract their reduction of overall Ca2 + load and related meta-
bolic stress, believed to be the neuroprotective mechanism of
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L-type-Ca2 + channel blockers in Parkinson’s disease (Surmeier
et al., 2012; Surmeier and Schumacker, 2013). However, if in
adult SN DA neurons, another calcium source, distinct from L-
type-Ca2 + channels, supports the NCS-1-dependent D2-autore-
ceptor responses (as we have first evidence for Cav1.3 knockout
mice), this would not be the case, and it could offer another po-
tential drug target for Parkinson’s disease therapy.
As blood–brain barrier permissive L-type-Ca2 + channel blockers
are already in clinical trials for neuroprotective Parkinson’s disease
therapy (ClinicalTrials.gov Identifier: NCT00909545; Simuni et al.,
2010; Parkinson Study, 2013), but as their general neuroprotective
mechanism, as well as the functional roles of L-type-Ca2 + chan-
nels in SN DA neurons are still unclear, our data provide an im-
portant first molecular step towards a better understanding of L-
type-Ca2 + channel function in SN DA neurons, and thus for tai-
lored pharmacological neuroprotective therapy. All molecular com-
ponents of the Cav1.3/NCS-1/D2-autoreceptor signalling network
are already accessible in humans to pharmacological modulation.
However, they are all expressed, in addition to in SN DA neurons,
in a variety of other neuronal and non-neuronal cells. Thus, future
studies need to address the specific acute and chronic patho-
physiological consequences, as well as side-effects of pharmaco-
logical modulation of Cav1.3/NCS-1/D2-autoreceptor-signalling in
SN DA neurons.
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